Syon Capital LLC Boosts Stake in Pfizer Inc. (NYSE:PFE)

Syon Capital LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.0% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 48,619 shares of the biopharmaceutical company’s stock after buying an additional 973 shares during the quarter. Syon Capital LLC’s holdings in Pfizer were worth $1,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the fourth quarter valued at about $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer in the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer during the 4th quarter worth approximately $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer during the 4th quarter valued at approximately $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer in the 4th quarter valued at $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

NYSE:PFE opened at $22.38 on Thursday. The firm has a market cap of $126.93 billion, a P/E ratio of 15.87, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The stock has a 50 day moving average of $24.69 and a two-hundred day moving average of $26.06. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the company earned $0.10 EPS. The firm’s revenue was up 24.7% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.69%. Pfizer’s dividend payout ratio is presently 121.99%.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on PFE. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday. They issued a “neutral” rating and a $24.00 price objective for the company. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group decreased their price target on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday, April 8th. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.57.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.